Spark CEO Marrazzo on Gene Therapy Pricing & Paving the Way for the Field
JANUARY 12, 2018
After decades of research and scientific ups and downs, the first U.S. gene therapy, a single, long-lasting treatment called voretigene neparvovec (Luxturna) for rare, inherited blindness, is now on the market. But the commercial challenge facing its developer, Spark Therapeutics, is daunting. Can Spark lead the way in showing that the new kinds of payment models it is experimenting with will succeed in getting the healthcare system to pay for such pricey, one-time treatments?